Analysis of Correlation between Prescription Drugs for Climacteric Disorders and CA Repeat Polymorphism of Estrogen Receptor .BETA. Gene

Abstract

To establish drug therapy for climacteric disorders based on CA repeat polymorphism in the estrogen receptor β gene, the present study investigated the issuance of prescriptions to patients with climacteric disorders in relation to CA repeat polymorphism. Prescription data used in this study included that for drugs that were prescribed for more than 3 months to 63 patients undergoing treatment for climacteric disorders. The 195 prescriptions analyzed included traditional Kampo medicines (49.7%), central nervous system medicines (26.7%) and Hormones (21.5%). The scale of combination therapy with Kampo to monotherapy with Kampo was 2.14 for SS genotype subjects, 1.43 for SL genotype subjects and 0.86 for LL genotype subjects. Thus the usage of combination therapy in SS subjects was 2.5 times greater than that in LL subjects. The percentages of the medicines predominantly prescribed for treatment of climacteric disorders-Kamishoyosan, Keishibukuryogan and Tokishakuyakusan-for each genotype were 72.7% for SS, 47.1% for SL and 38.5% for LL, and the percentage for the SS genotype was significantly higher than that for the LL genotype. The prescription rate for Keishibukuryogan for patients with the SS genotype was 31.8% versus 10.0% for the other 2 genotypes, the rate for SS being significantly higher.In conclusion, the use of CA repeat polymorphism in addition to symptoms in the selection of drugs for climacteric disorders may allow therapy to be personalized.